Expert Review of Neurotherapeutics最新文献_第2页

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-23 DOI: 10.1080/14737175.2024.2445016

Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi

{"title":"Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.","authors":"Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi","doi":"10.1080/14737175.2024.2445016","DOIUrl":"10.1080/14737175.2024.2445016","url":null,"abstract":"Introduction: After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like proportions. In order to avoid mystifying or demonizing the properties of 5-HT2a agonists on emotional grounds, this subject requires a strictly unprejudiced and cautious approach to the evidence.Areas covered: In this article, the authors attempted to comprehensively analyze the available literature to provide a balanced overview of the possible benefits of psychedelics in healthcare, taking into account their potential risks.Expert opinion: To date, psychedelics have shown a therapeutic potential in a wide range of conditions, with a seemingly limited risk of inducing adverse reactions, including abuse and dependence, when administered in a controlled environment by specialized personnel. In any case, although several questions remain unanswered before drawing firm conclusions, further studies are needed to establish which conditions and subjects could benefit from psychedelics and which patients bear the greater risk of adversities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment strategies for patients with spinal muscular atrophy.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-10 DOI: 10.1080/14737175.2024.2439486

Liesbeth De Waele, Laurent Servais

引用次数: 0

What are the main challenges in the treatment of neonatal hypoxic ischemic encephalopathy?

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-10 DOI: 10.1080/14737175.2024.2438649

Francesco Pisani, Carlotta Spagnoli

引用次数: 0

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1080/14737175.2024.2434079

Lars Edvinsson

{"title":"Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence.","authors":"Lars Edvinsson","doi":"10.1080/14737175.2024.2434079","DOIUrl":"10.1080/14737175.2024.2434079","url":null,"abstract":"Introduction: Rimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine.Areas covered: A brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant.Expert opinion: Several clinical trials established rimegepant as a safe and effective treatment (acute and preventive) of migraine in adults. There are few head-to-head studies with other migraine treatments to determine relative efficacy. However, the favorable safety profile of rimegepant makes it appropriate for many patients, particularly those with contraindication, intolerance, or inadequate response to other classes of standard-of-care migraine treatments. Additional studies on the efficacy and cost-effectiveness relative to other treatments may further define the role of rimegepant in migraine treatment.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1141-1155"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder. 英国医用大麻登记处：对开具大麻精油和干花治疗广泛性焦虑症的患者进行的队列研究。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-11-11 DOI: 10.1080/14737175.2024.2423634

John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder.","authors":"John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1080/14737175.2024.2423634","DOIUrl":"10.1080/14737175.2024.2423634","url":null,"abstract":"Background: Generalized anxiety disorder (GAD) is a common mental health condition. The endocannabinoid system has become a focus for new therapies, increasing interest in cannabis-based medicinal products (CBMPs). This study uses data from the UK Medical Cannabis Registry (UKMCR) to investigate real-world outcomes and safety of different CBMP formulations in GAD patients.Methods: This study analyzed patient-reported outcomes from 302 GAD patients prescribed CBMPs (oil-based, dried flower, or a combination). Anxiety (GAD-7), sleep quality (SQS), and quality of life (EQ-5D-5 L) were assessed at 1, 3, 6, and 12 months. Adverse events were recorded.Results: All CBMP formulations were associated with improvements in anxiety, sleep, and quality of life over 12 months (p < 0.050). At 12 months, there were no significant differences in outcomes between formulations (p > 0.050). The majority of reported adverse events (n = 707) were mild (n = 343) or moderate (n = 285) in severity, with no life-threatening events observed.Conclusion: This study provides real-world evidence supporting the potential of CBMPs for improving GAD symptoms. Patients prescribed both oil-based and dried flower formulations have similar outcomes over 12 months. Further research is needed to determine the optimal CBMP formulation and long-term effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1193-1202"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal zavegepant for the acute treatment of migraine. 用于偏头痛急性期治疗的zavegepant气雾剂。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1080/14737175.2024.2405741

Guy Greco, Teshamae Monteith

{"title":"Intranasal zavegepant for the acute treatment of migraine.","authors":"Guy Greco, Teshamae Monteith","doi":"10.1080/14737175.2024.2405741","DOIUrl":"10.1080/14737175.2024.2405741","url":null,"abstract":"Introduction: Migraine is a highly prevalent chronic, inherited neurological condition of the brain which carries a significant level of disability. Despite advances, there is an unmet need for more effective therapies.Areas covered: Zavegepant nasal spray is a recent therapeutic option which acts as a calcitonin gene-related peptide receptor antagonist. The objective is to review the efficacy, safety, and additional results of the most recent trials investigating intranasal zavegepant for the acute treatment of migraine with or without aura. The authors searched PubMed using the keywords 'zavegepant,' 'Zavzpret,' 'migraine,' 'calcitonin gene-related peptide,' 'CGRP receptor antagonists.' This article covers Phase 1, Phase 2/3, and Phase 3 randomized, double-blind, placebo-controlled trials to evaluate the efficacy of intranasal zavegepant for treatment of acute migraine attacks.Expert opinion: Intranasal zavegepant is an efficacious, safe, and tolerable anti-migraine drug based on clinical trials and clinical experience. It is especially useful for patients who experience attacks of sudden onset, those with nausea or vomiting, or a high cardiovascular risk burden. Dysgeusia was common; future studies are needed to better characterize this adverse event. Head-to-head studies are lacking with other migraine-specific therapies; the decision to treat should be patient-centered, with attack-specific characteristics in mind.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1131-1140"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behavioural Therapy for tic disorders: a comprehensive review of the literature. 治疗抽搐症的行为疗法：文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-22 DOI: 10.1080/14737175.2024.2405740

Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim

{"title":"Behavioural Therapy for tic disorders: a comprehensive review of the literature.","authors":"Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim","doi":"10.1080/14737175.2024.2405740","DOIUrl":"10.1080/14737175.2024.2405740","url":null,"abstract":"Introduction: Behavioral therapies are recommended as a first-line intervention for Tourette syndrome and persistent motor or phonic tic disorder.Areas covered: In this review, the authors summarize randomized controlled trials on the comprehensive behavioral intervention for tics (CBIT), habit reversal therapy (HRT), and exposure and response prevention (ERP). Studies of face-to-face treatment, treatment by video conferencing, group treatment, and internet delivered treatment were assessed, as well as evidence of treatment predictors, modifiers, and mediators.Expert opinion: There is high-quality evidence for face-to-face one-on-one treatment with CBIT, and data suggesting that one-on-one treatment by videoconference provides similar benefit. Limited data on group treatment with CBIT/HRT suggests inferiority to individual treatment, while internet-based CBIT programs appear more beneficial than wait list or psychoeducation. There is one face-to-face one-on-one treatment comparison of ERP to HRT, suggesting equal benefit. Internet-based ERP with minimal therapist support appears effective, although effect sizes are small. One study using behavioral therapy with ERP or HRT found similar benefit to medical treatment with antipsychotics. Data on predictors, modifiers, and mediators of treatment efficacy are emerging. In summary, behavioral therapies are an important treatment modality for tic disorders. Furthermore, important efforts to improve treatment accessibility are underway.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1181-1191"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the current and emerging treatment options for vestibular migraine. 前庭性偏头痛的现有和新兴治疗方案概览。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1080/14737175.2024.2405739

Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros

{"title":"An overview of the current and emerging treatment options for vestibular migraine.","authors":"Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros","doi":"10.1080/14737175.2024.2405739","DOIUrl":"10.1080/14737175.2024.2405739","url":null,"abstract":"Introduction: Vestibular migraine is a relatively common syndrome characterized by the occurrence of vertigo and other vestibular symptoms, frequently -but not always- accompanied by migraine symptoms, such as headache, photophobia, and phonophobia.Areas covered: The authors review the acute or abortive treatment during an attack and prophylactic treatment of vestibular migraines, including pharmacological and non-pharmacological options.Expert opinion: Since its recognition as an independent clinical entity is recent, studies concerning its different treatment alternatives are still scarce, and the level of evidence of published studies is generally low. For acute treatment, although available data are conflicting, triptans are usually tried first. Neurostimulating devices can also be considered for acute treatment of vestibular migraine. Regarding the preventive treatment of vestibular migraine, based on the results of two randomized clinical trials and its pharmacological properties, flunarizine should be considered as the first treatment option. Second-line preventive treatments encompass propranolol, topiramate, venlafaxine, and valproic acid. Among non-pharmacological options, vestibular rehabilitation seems to be a sound prophylactic treatment option.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1157-1179"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can pharmacotherapy help to reduce trichotillomania? 药物疗法有助于减轻毛发躁动症吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2398471

Michael Thomson, Verinder Sharma

引用次数: 0

Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry. 更年期及其对氟马尼珠单抗预防偏头痛疗效的影响：对希腊前瞻性真实世界登记的事后分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-16 DOI: 10.1080/14737175.2024.2403576

Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis

{"title":"Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.","authors":"Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis","doi":"10.1080/14737175.2024.2403576","DOIUrl":"10.1080/14737175.2024.2403576","url":null,"abstract":"Objective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III, would differ between pre-menopausal and post-menopausal women.Methods: A total of 171 (aged 18-70 years) fremanezumab-treated female migraine patients for six consecutive months were classified to those at pre-menopausal (n = 82) or post-menopausal (n = 89). Monthly headache days (MHD), disability, and quality of life (QOL) outcomes were assessed at baseline and at week 24 post-fremanezumab within subgroups and were then compared between them. Safety and tolerability were also assessed.Results: In both groups, fremanezumab demonstrated significant reductions in MHDs, reduced disability, and higher QOL scores at week 24 post-treatment, compared to baseline. However, the between-subgroup comparison documented that pre-menopausal women and those at post-menopausal comparably benefited with significant reductions in overall MHDs (p = 0.883). Less disability, according to MIDAS (p = 0.696) and HIT-6 scores (p = 0.912), as well as higher QOL scores at week 24 post-fremanezumab, were also comparably evident in both groups. Safety was excellent across both subgroups.Conclusion: Fremanezumab can be considered a very effective treatment option for preventing migraines in difficult-to-treat women, aged 18-70 years, regardless of their menopausal status.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1119-1126"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0